Lates News

According to the AI flash report of Every Economics, Guojin Securities released a research report on August 22, giving Anke Biotechnology (300009.SZ) a buy rating. The main reasons for the rating include: 1) the continuous development of the main business, the overall performance of the parent company is stable; 2) actively expanding new businesses, opening up new growth points for performance; 3) laying out cutting-edge technology, accelerating innovation and research and development. (Daily Economic News)